ANGIODESIGN

• 20590 - Manufacture of other chemical products n.e.c.

AngioDesign is a limited company, registered under the laws of England and Wales, whose eligible shares qualified for UK EIS tax relief from 2014 and that is held and funded privately, having historically received funding from the UK's Wellcome Trust and others. In 2019, AngioDesign became a member of the UK BioIndustry Association (BIA), a trade association representing bioscience and pharmaceutical companies, academic, research and philanthropic organisations, and service providers to the biosciences sector... AngioDesign is developing the first truly-novel, next-generation combination inhibitors (C-domain ACE, C-domain ACE/NEP, N-domain ACE) with the potential to treat a number of the most important conditions impacting human health today, including heart failure, hypertension and fibrosis. Cardiovascular disease is the single most common cause of death in the world... AngioDesign is developing domain-selective ACE inhibitors, alone and in combination with other inhibitors, which..

Also known as: Angiodesign (UK), ANGIODESIGN (UK) LTD

Previous names: NESSEAN LIMITED

Registration numbers: 04212911 (CH)

Primary location: Warminster United Kingdom